- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 23, 2025
Product Development
Degraders, bispecifics define translational trends at AACR
Plus: New targets involving glycosylation, angiogenesis and more
BioCentury | Feb 23, 2023
Deals
Redx adds U.S. office while Jounce shareholders eye CVR’s upside in merger
Combined company will prioritize U.K. company’s ROCK2 program as deal adds to Redx’s balance sheet
BioCentury | Jun 7, 2022
Finance
Zurich-based ImmunOs taps U.S.-EU syndicate for $74M series B, expands footprint
Swiss immuno-oncology start-up building presence in Maryland as lead HLA-derived program nears clinic
BioCentury | Apr 8, 2022
Discovery & Translation
Young companies taking on checkpoint inhibitor resistance at AACR22
Ten companies you may not have heard of tackling checkpoint resistance at AACR22
BioCentury | Nov 13, 2020
Translation in Brief
Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more
BioCentury’s roundup of translational news
BioCentury | Sep 26, 2020
Product Development
Merck’s myeloid data add support for the emerging target class
Merck strengthens oncology pipeline beyond Keytruda with a trio of ESMO readouts
BioCentury | Jun 6, 2020
Product Development
June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J
BioCentury | Mar 29, 2019
Targets & Mechanisms
AACR moves in a myeloid direction
A survey of the hot topics covered in this year’s AACR abstracts
BioCentury | Mar 2, 2018
Product R&D
Sigma for synapses
How Cognition plans to protect synapse function in AD via sigma-2
Items per page:
1 - 10 of 13